Biotechnology
Commercial strategy and market intelligence for biotechnology companies — helping platform and asset teams make high-confidence decisions with limited internal data.
Biotech companies often move faster than their internal market data can keep up with, and the strategic questions — which indication, which partner, when to scale manufacturing — carry outsized consequences. We help biotech leadership, business-development and portfolio teams answer those questions with rigorous, independent market intelligence and modelling rather than gut feel.
How we help Biotechnology teams
- Opportunity sizing and indication prioritization for platforms and pipeline assets
- Partnering, licensing and out-licensing intelligence and target identification
- Competitive and modality landscape tracking (including emerging modalities)
- Manufacturing-readiness and CDMO strategy as programs approach scale
- Commercial due diligence to support fundraising and partnering conversations
Questions we help answer
- Which indication or application should our platform pursue first?
- Who are the most credible partners or acquirers, and how do we reach them?
- How ready is our manufacturing route as we approach commercial scale?
- What market evidence strengthens our fundraising or partnering story?
How we work
Every engagement is designed around a specific decision and delivered by sector-specialist analysts, with transparent assumptions and Excel- or dashboard-backed models you can interrogate. We draw on the proprietary research infrastructure of the InsightAce Analytic group and tailor each output to how your team actually makes decisions.